In Brief Welsbie et al. use high-throughput wholegenome siRNA-based screening in primary retinal ganglion cells to identify novel pathway members of DLKmediated axon injury signaling, including the related kinase LZK and the transcription factors, MEF2A and SOX11.
INTRODUCTION
Neuronal cell death in response to axon injury is a key feature of many neurodegenerative diseases. For example, axonal injury triggers the death of projection neurons called retinal ganglion cells (RGCs) , resulting in vision loss in a group of diseases known as optic neuropathies. The most common of the optic neuropathies, glaucoma, is expected to blind nearly 11 million people worldwide by 2020 (Quigley and Broman, 2006) . While a component of glaucomatous injury is intraocular pressure related, lowering pressure can be challenging in some patients, and in others, RGC damage continues despite pressure lowering. Thus, the development of effective neuroprotective strategies could complement pressure lowering by mitigating the RGC response to injury. This makes the RGC both a useful model to study neurodegenerative cell death signaling and, in and of itself, a highly disease-relevant neuron.
In response to axon injury, neurons execute an active genetic program that leads to axonal degeneration and, eventually, cell death. In axon degeneration signaling, this requires Sterile Alpha and TIR Motif Containing 1 (SARM1) and mitogen-activated protein kinase (MAPK) activation (Gerdts et al., 2013; Osterloh et al., 2012; Yang et al., 2015) . To identify the signaling components responsible for cell death, using an unbiased approach, we developed a method for delivering small interfering RNA (siRNA) to primary mouse RGCs and performed a high-throughput, functional genomic screen of kinases involved in RGC cell death (Welsbie et al., 2013) . This and other work identified dual leucine zipper kinase (DLK) as being a key mediator of RGC cell death in response to axon injury (Fernandes et al., 2014; Watkins et al., 2013; Welsbie et al., 2013) . Moreover, DLK is involved in the signaling associated with axon degeneration and regeneration (Miller et al., 2009; Watkins et al., 2013; Yang et al., 2015) . This, along with its druggability, makes DLK an attractive neuroprotective target for chronic neurodegenerative diseases like glaucoma that are associated with low-level, repeated injury.
To further define the molecular network involved in RGC cell death signaling, we have developed a series of novel highthroughput functional genomic screens. Here we show that DLK cooperates with a related kinase, leucine zipper kinase (LZK), to trigger activation of downstream kinases including mitogen-activated protein kinases 4 and 7 (MKK4/7) and JUN N-terminal kinases 1-3 (JNK1-3). We identify the four downstream transcription factors, JUN, activating transcription factor 2 (ATF2), myocyte-specific enhancer factor 2A (MEF2A), and SRY-Box 11 (SOX11), as being required for full DLK/LZK-mediated cell death. Additionally, supporting the potential development of DLK/LZK inhibition as a viable therapeutic strategy for human neurodegenerative disease, we demonstrate that treatment of human stem cell-derived RGCs with a protein kinase inhibitor (PKI) with activity against DLK and LZK potently promotes human RGC survival. Finally, we identify an already FDAapproved PKI, sunitinib, as also being protective of human RGCs.
RESULTS

Sensitized Kinome Screen Identifies LZK as a Mediator of RGC Cell Death
In the process of exploring various small-molecule-and genomic-based strategies for DLK inhibition, we repeatedly observed that PKIs with activity against DLK were more efficacious than siRNA-mediated knockdown of DLK in their ability to promote survival of primary mouse RGCs (Welsbie et al., 2013) . To exclude the possibility that the difference in activity was due to residual levels of DLK activity remaining after siRNA-mediated knockdown, we tested the effect of Cre recombinase-mediated DLK knockout ( Figure 1A ). Primary RGCs were immunopanned from floxed Dlk mice (Miller et al., 2009 ), transduced with adenovirus expressing Cre or a GFP control, and then treated with maximally protective doses of the DLK inhibitor, tozasertib, or a vehicle control. After 2 days, to allow time for turnover of extant DLK, immunopanning injury was exacerbated by the addition of colchicine, which destabilizes microtubules and engages axon injury signaling cascades, including DLK (Bounoutas et al., 2011; Miller et al., 2009; Valakh et al., 2013 Valakh et al., , 2015 . After an additional 2 days, viability was measured with CellTiter-Glo, an ATP-based luminescence assay that highly correlates with survival measured by conventional stains of viability and automated image analysis ( Figure S1A ). Similar to the results with siRNA-mediated knockdown, genetic deletion of Dlk was protective but markedly less so than pharmacologic inhibition. This suggested that PKIs like tozasertib might be inhibiting one or more additional kinase targets that cooperate with DLK to promote cell death and that simultaneous inhibition of both was required to promote maximal RGC survival.
In order to identify the other putative kinase target(s), we modified our original siRNA screen (Welsbie et al., 2013) to include Dlk siRNA in every well, thereby sensitizing it to those kinase siRNAs that synergized with DLK knockdown to further increase RGC survival ( Figure 1B) . Using this approach, we re-screened a library of 1,869 siRNAs, targeting 623 kinases, for the ability to increase RGC survival after a colchicine challenge. The top gene nominated by the screen was Lzk (Map3k13), hitherto unknown to have any role in disease or neuronal survival. Given the abundance of false-positive hits from siRNA screens (H) Survival (±SD) of WT RGCs, transfected with siPOOLs and cultured in tozasertib, 2 days after colchicine (1 mM) addition. (Bushman et al., 2009; Schultz et al., 2011) , we sought to validate the findings by using the ''redundancy and rescue'' approach (Echeverri et al., 2006) . First, RGCs were treated with four new Lzk siRNAs, with sequences not tested in the initial screen, and their effect on LZK levels ( Figure S1B ) and cell survival ( Figure 1C) were assessed. While none of the four siRNAs had survival-promoting activity by themselves, explaining why our first kinome screen did not identify LZK, in the setting of DLK knockdown, all four robustly increased RGC survival. As another layer of validation, we turned to siPOOLs. These are pools of approximately 30 siRNAs targeting a common mRNA, thereby diluting out offtarget effects while maintaining on-target silencing (Hannus et al., 2014) . Primary RGCs were transfected with control siPOOLs or siPOOLs targeting Dlk and/or Lzk and assayed for protein expression using a capillary-based immunoassay (Protein Simple). As expected, each siPOOL knocked down its cognate target ( Figure S1C ) and simultaneous knockdown of both DLK and LZK increased the suppression of JNK signaling ( Figure 1D ). In the survival assay, Lzk siPOOLs alone had little effect on survival, but synergized with Dlk siPOOLs to greatly increase survival ( Figure 1E ). By comparison, simultaneous addition of the neurotrophin brain-derived neurotrophic factor (BDNF), glia-derived neurotrophic factor (GDNF), and ciliaryderived neurotrophic factor (CNTF) led to a far less robust increase in RGC survival but did modestly increase the effect when combined with DLK/LZK knockdown ( Figure 1F ). Conventional stains of viability and automated fluorescent microscopy confirmed that the survival increase was not an artifact of the luminescence assay ( Figure S1D ) and that the effect was sustained ( Figure S1E ). As one further confirmation, we showed that the effect of LZK on cell death could be reconstituted after siRNA-mediated dual DLK/LZK knockdown by expressing mouse siRNA-resistant human LZK cDNA (Figures S1F and S1G). Additionally, we found that DLK and LZK can have an additive role in promoting neurite outgrowth, an in vitro surrogate for axon regeneration (Figures S1H and S1I). As a complementary approach to explore LZK's effect on RGCs, we expressed a point mutant of human LZK (K195A) that lacks kinase activity and should function as a dominant negative (Ikeda et al., 2001a) . Unexpectedly, even without inhibiting DLK, the K195A LZK mutant had robust survival-promoting activity that was dependent on its dimerization domain (Figure S1J) . Since this suggested that the dominant negative might also be interfering with DLK signaling, possibly by heterodimer formation, we next asked whether DLK and LZK interacted either directly or indirectly. Endogenous DLK was immunoprecipitated from primary RGCs and immunoassayed for LZK, or vice versa ( Figure S1K ). In both cases, DLK and LZK co-immunoprecipitated, suggesting that they indeed participate in a common endogenous complex. Taken together, these results suggest that LZK signaling can partially compensate for DLK in activating RGC cell death and that simultaneous inhibition is required to arrest the cell death program.
LZK and DLK Are the Key Targets of Neuroprotective PKIs LZK is a 959 amino acid member of the mixed-lineage kinase (MLK) family of kinases (Sakuma et al., 1997) . To determine whether other MLKs also had a role in RGC cell death, but were simply missed by the initial kinome screens, we tested four additional, independent siRNA sequences for each member of the MLK family. Perhaps surprisingly, LZK was the only MLK whose knockdown synergized with DLK knockdown to promote primary RGC survival ( Figure 1G ). Based on these results, we hypothesized that LZK might be the as-yet-unidentified ''missing target'' of our neuroprotective PKIs. In fact, while LZK shares only 60% overall homology with DLK, the kinase domain, the target of small molecule inhibitors, is 86% conserved. Moreover, kinase profiling has demonstrated that each one of the neuroprotective PKIs (i.e., tozasertib, foretinib, crizotinib, lestaurtinib, and KW2449) has biochemical activity against both purified DLK and LZK . We reasoned that if LZK and DLK were the relevant targets of the neuroprotective PKIs, individual knockdown of either kinase should sensitize the cells to subthreshold concentrations of tozasertib. Consistent with this hypothesis, knockdown of either DLK or LZK left-shifted the dose-response curve to tozasertib ( Figure 1H ). Additionally, simultaneous knockdown of both DLK and LZK fully recapitulated the protective effect of the drug and further addition of tozasertib did not produce a significant increase in survival. Although we cannot rule out minor contributions from other kinases, the major survival-promoting effect of neuroprotective PKIs appears to be mediated by the simultaneous inhibition of DLK and LZK. , g-synuclein in situ hybridization (Soto et al., 2011) , or injection of retrograde tracers (Vidal-Sanz et al., 1988) . Unfortunately, these methods can be difficult to quantify, have limited specificity, are labor intensive, and/or are incompatible with optic nerve injury models that downregulate RGC markers (Mead et al., 2014; Soto et al., 2008) . We adapted a flow cytometry (FC)-based approach (Chang et al., 2012) to use two intracellular antigens, b-III-tubulin (TUBB3) and g-synuclein (SNCG), that are expressed by RGCs ( Figure S2A ) but not downregulated after injury. Retinas from wild-type (WT), uninjured mice were isolated, dissociated, stained, and analyzed by FC. As expected, 0.8%-1.0% of total retinal cells were double positive for TUBB3/ SNCG, consistent with past estimates of RGC frequency (Williams et al., 1996) . Moreover, the intersection of SNCG and TUBB3 staining by FC was both highly specific and sensitive for RGCs immunopanned from neonatal retina ( Figure S2B ) or dissociated in adult retina ( Figure S2C ). SNCG and TUBB3 staining was preserved after optic nerve injury ( Figure S2D ), allowing for quantification in the mouse optic nerve crush (ONC) model ( Figure S2E ). Finally, we showed that the FC technique identifies a similar reduction in RGC survival 2 weeks after ONC when compared to traditional imaging of immunostained flatmounted retinas (71% versus 75%, respectively; Figure S2F ).
Targeted Disruption of LZK Confirms that LZK Plays a Role in RGC Survival In Vitro and In Vivo
In light of the perinatal lethality associated with homozygous Dlk disruption (Hirai et al., 2006) , we took a ''knockout first'' approach in order to generate mice with targeted deletion of Lzk. An Lzk null allele was engineered by targeting a promoterless splice acceptor/b-galactosidase cassette (Skarnes et al., 2011) to the second exon of Lzk in C57BL/6 mice and then further converted into a conditional deletion by crossing to FLP-expressing mice ( Figure 2A ). Interestingly, unlike the situation with Dlk, mice homozygous for the null Lzk allele were both viable and fertile, exhibiting no obvious phenotype. We then isolated RGCs from either WT or Lzk null mice and assayed for LZK expression (Figure 2B) . As was the case with DLK, LZK is robustly upregulated 24 hr after immunopanning (which necessarily axotomizes the cells), but only in WT mice, confirming the specificity of our antibody and the validity of our knockout strategy.
To evaluate whether knockout of LZK was protective in vivo, Lzk null or WT control mice were subjected to ONC or sham control. Two weeks later, allowing time for the wave of RGC cell death that follows axon injury, retinas were isolated and the number of surviving RGCs was quantified by FC. Lzk knockout did not promote RGC survival in vivo ( Figure 2C ), which was not surprising given the minimal effect of Lzk siRNAs in vitro. We next crossed floxed Lzk mice with floxed Dlk mice (Miller et al., 2009) LZK levels were reduced after Cre-mediated recombination ( Figure 2D ), RGCs were isolated from each strain and transduced with Cre or GFP control adenovirus. After 2 days, the cells were challenged with colchicine and survival was measured an additional 2 days later ( Figure 2E ). While genetic disruption of Dlk had a modest effect on survival (consistent with the 2-to 4-fold increase seen previously), simultaneous knockout of Dlk and Lzk synergistically increased RGC survival (up to 100-fold), validating the siRNA findings. In order to extend the findings in vivo, floxed Dlk, floxed Dlk/Lzk and WT mice received an intravitreal injection of adeno-associated virus 2 (AAV2) expressing Cre. After 2 weeks to allow time for recombination to occur, ONC or sham surgery was performed and the number of surviving RGCs was assayed by FC after an additional 2 weeks (Figure 2F ). While targeted deletion of Dlk was partially protective, simultaneous targeting of both Dlk and Lzk led to increased survival, nearing uninjured levels when accounting for the percentage of retina that was transduced by the virus (dotted lines).
DLK/LZK Inhibition with an FDA-Approved PKI Protects Human Stem Cell-Derived RGCs
In order to test whether the DLK/LZK pathway had a similar role in human RGCs (hRGCs), we turned to human stem cell-derived RGCs. We previously described a method for differentiating and purifying hRGCs that utilizes an embryonic stem cell (hESC) reporter line that was generated using clustered regularly interspaced short palindromic repeats (CRISPR) technology to knock a P2A-mCherry cassette into the BRN3B (POU4F2) locus (Sluch et al., 2015) . RGCs differentiated from this line demonstrate morphological, ultrastructural, gene expression, and electrophysiological properties consistent with hRGCs. For the studies described here, we used a modified version of this approach, based upon an improved cell line, which incorporates a P2A-tdTomato-P2A-Thy1.2 reporter cassette (V.M.S., X.C., Melissa M. Liu, C.A.B., Jie Cheng, K.L.M., D.S.W., and D.J.Z., unpublished data). After anti-Thy1.2 immunopurification, hRGCs were challenged with colchicine as a pharmacologic model of axonal injury (Miller et al., 2009 ) and survival was measured 48 hr later using CellTiter-Glo ( Figure 3A ) or conventional stains of viability (data not shown). As with primary mouse RGCs, colchicine killed the vast majority of hRGCs and the effect was reversed with the dual DLK/LZK-inhibitor tozasertib and a structurally distinct, high-potency DLK (Cohen et al., 2013) that similarly inhibits LZK (data not shown). With the goal of potentially developing DLK/ LZK inhibition as a treatment approach for optic neuropathies and other forms of neurodegenerative disease, we tested the FDA-approved drug sunitinib in the hRGC axonal injury assay. Sunitinib, which is approved for treatment of renal cell carcinoma and gastrointestinal stromal tumor, is a broad spectrum PKI with activity against both DLK and LZK Karaman et al., 2008; Rock et al., 2007) . As shown in Figure 3B , sunitinib potently and in a dose-dependent manner promotes the survival of hRGCs challenged by colchicine-induced axonal injury.
LZK and DLK Trigger RGC Cell Death through a JNK-and MKK-Dependent Kinase Cascade In C. elegans, the LZK homolog DLK-1 has an intrinsic calciumsensing motif that, in response to axonal injury, binds calcium and leads to kinase activation (Yan and Jin, 2012) . Given that the motif is conserved in mammalian LZK, we asked whether the same mechanism was active in RGCs. WT RGCs were immunopanned and tested in the human LZK reconstitution assay described above, comparing WT and mutant LZK ( Figure 4A ). A deletion of the homologous calcium-sensing domain (D6), but not a mutation which renders the kinase domain inactive, had activity comparable to WT LZK, demonstrating that the calcium-sensing motif is not necessary for LZK's ability to promote cell death, at least in the setting of overexpression, but that active kinase signaling is required. DLK/LZK, and homologs in lower organisms, have been shown to signal through two downstream MAPK pathways, p38 and JNK (Bounoutas et al., 2011; Fan et al., 1996; Tulgren et al., 2011) . While we have consistently failed to observe survival-promoting activity with p38 inhibitors (data not shown), both kinase screens identified knockdown of MKK4 and MKK7, both JNK kinases, as survival promoting. In order to confirm a role for MKK4/7 and JNK1-3 in RGC cell death, we isolated primary RGCs from Mkk4/7 (Mazzitelli et al., 2011) and Jnk1-3 conditional knockout mice and transduced them with Cre or GFP adenovirus. As expected, deletion of Jnk1, Jnk2, and Jnk3 (Figure 4B ) or Mkk4 and Mkk7 ( Figure 4C ) increased RGC survival, more than individual knockout of Mkk4 or Mkk7 (data not shown). We then combined the human LZK reconstitution assay with knockout of each tier to examine whether LZK had cell death-promoting activity that signaled outside of the MKK4/7, JNK1-3 axis. RGCs were isolated from WT, floxed Mkk4/Mkk7, or floxed Jnk1, Jnk2/3 null mice, transfected with Dlk and Lzk siPOOLs, and transduced with Cre-or GFP-expressing adenovirus. After 2 days, RGCs were challenged with GFP or human LZK-expressing adenovirus to reconstitute LZK signaling, and then survival was measured after an additional 2 days. LZK reconstitution promoted cell death in WT cells, but this activity was attenuated when only Jnk1 was present and completely absent when all three Jnk genes were deleted ( Figure 4D ). Simultaneous knockout of Mkk4 and Mkk7 also rendered RGCs insensitive to LZK reconstitution ( Figure 4E ). On the other hand, individual knockout of Mkk4 or Mkk7 was only modestly protective (data not shown). A similar pattern of results was seen when the pathway was reconstituted by expressing siRNA-insensitive rat Dlk cDNA (data not shown). Together, these results suggest a linear cascade in which DLK and LZK activate MKK4 and MKK7, which in turn, leads to JNK1-3 activation and, ultimately, cell death.
Arrayed, Whole-Genome siRNA Screen in Primary RGCs
In order to identify non-kinase genes that are involved in RGC cell death signaling, we expanded our kinase screen and assayed an arrayed, whole-genome library of 52,725 siRNAs, providing 3-fold coverage of 17,575 genes, for each siRNA's ability to promote RGC cell survival ( Figure 5A ). Since seed-based off-target effects can dominate the results of siRNA screens looking at complex phenotypes like survival (Jackson et al., 2003 (Jackson et al., , 2006 , we used bioinformatic signal correction approaches to take advantage of the extensive and redundant dataset provided by the whole-genome screen, which included nearly every possible seed combination multiple times. In one approach, we tracked the survival effect of every seed sequence within the library and used this information to generate a correction factor to subtract out off-target contributions, resulting in ''corrected'' on-target cell survival-promoting activities . Using this common-seed method, we generated a rank order of the genes whose median siRNA had the most survival-promoting activity ( Figure S3A ). In a second approach, we predicted the potential off-target mRNAs that are being silenced by the bioactive seed sequences and then used a Haystack analysis to identify commonly targeted genes by similarly behaving seeds in order to deconvolute the off-target effects and identify the genes whose off-target silencing affects survival . This latter approach nominated a distinct but overlapping set of genes ( Figure S3B ). Validating the approach, kinases known to be involved in RGC cell death, including Map2k4/ Mkk4, Map2k7/Mkk7, and Map3k12/Dlk, were among the top hits. We then used independent siRNAs to test the other genes nominated by the on-target ( Figure S3C ) and off-target analyses ( Figure S3D ) and were able to replicate the survival-promoting activity ( Figure 5B ) associated with knockdown ( Figure S4A ) of three genes: Atf2, Mef2a, and Bbc3/Puma. Finally, we tested siPOOLs for their ability to knockdown ATF2, MEF2A, and PUMA levels ( Figure S4B ) and confirmed that knockdown of each one improved RGC survival in vitro ( Figure 5C ).
In peripheral sensory neurons, neurotrophin deprivation activates the Puma promoter through the transcription factors, FOXO3A and JUN, thereby integrating the activity of the prosurvival AKT and pro-death JNK pathways (Ambacher et al., 2012; Simon et al., 2016) . The resulting increase in PUMA levels leads to cell death and axon degeneration. That we identified knockdown of PUMA as being survival promoting suggested that the pathway might be similar in injured CNS neurons like RGCs. Indeed, RGC axon injury in vivo leads to an upregulation of Puma transcripts that is both JUN (Fernandes et al., 2013) and DLK (Watkins et al., 2013) dependent. However, in the primary RGC survival assay, neither PUMA knockdown nor JUN knockdown was able to fully rescue cell death (data not shown) and, in vivo, targeted deletion of either Jun or Puma only serves to delay, but not prevent, cell death following optic nerve injury (Fernandes et al., 2012; Libby, 2011, 2013; Yoshida et al., 2002 ). Since our screen identified ATF2, a known heterodimeric partner of JUN, and since axon injury was known to trigger phosphorylation of ATF2 (Levkovitch-Verbin et al., 2005), we queried whether ATF2 inhibition was required to prevent RGC cell death. To test this, we obtained floxed Atf2 mice (Shah et al., 2010) , in which Cre-dependent recombination triggers an in-frame deletion of portions of the DNA-binding and dimerization domains ( Figure S4C ). While targeted disruption of Atf2 increased RGC survival, albeit modestly, in vitro (Figure S4D) and in the mouse model of ONC ( Figure S4E ), combined knockdown of ATF2 and JUN was still unable to fully rescue cell death (data not shown). This suggested the possibility that in the absence of ATF2/JUN, unlike the case with sensory neurons, RGC cell death signaling might additionally proceed through other transcription factors. Based on our siRNA results, we hypothesized that MEF2A might be one of these other factors. 
MEF2A Is a DLK-Regulated Mediator of RGC Cell Death
To validate the siRNA findings and test whether the transcriptional-regulatory function of MEF2A was critical for RGC cell death, we utilized conditional Mef2a knockout mice in which the second coding exon of Mef2a is floxed and Cre-dependent recombination produces an in-frame deletion that disrupts the DNA-binding MADS-box and MEF2 domains (Akhtar et al., 2012) . As expected, RGCs isolated from the floxed mice displayed a shift in the size of MEF2A in response to Cre expression ( Figure 6A ). To test the effect on survival, we isolated RGCs from WT or floxed Mef2a mice, transduced them with adenovirus expressing Cre or a GFP control, and then measured viability 2 days after a colchicine challenge ( Figure 6B ). While increasing amounts of Cre-expressing adenovirus had no effect on WT RGCs, it led to a modest, but dose-dependent, increase in survival of floxed Mef2a RGCs. We then considered the possibilities that dominant-negative forms of MEF2A were interfering with the signaling of other highly related MEF2 family members, including MEF2C and MEF2D. However, arguing against this possibility, RGCs isolated from mice with combined conditional deletions of Mef2a, Mef2c, and Mef2d (Akhtar et al., 2012) had no reversal of the phenotype associated with Mef2a knockout ( Figure 6C ). To confirm these findings in vivo, we intravitreally injected WT or floxed Mef2a mice with AAV2 expressing Cre and then, after 2 weeks, subjected them to ONC or sham surgery. After an additional 2 weeks, retinas were harvested and assayed for RGC survival using the TUBB3/SNCG FC technique described above ( Figure 6D ). Consistent with the in vitro findings, targeted disruption of the MEF2A transcriptional regulatory domains increased RGC survival. Since we had demonstrated that MEF2A played a role in RGC cell death, we considered the obvious possibility that it was somehow regulated by DLK/LZK, or downstream JNK, signaling. First, we sampled several antibodies against known phosphosites and found that S408, whose phosphorylation is associated with inactive or transcriptionally repressive forms of MEF2A (Flavell et al., 2006; Shalizi et al., 2006) , could be reliably quantified in vivo using an FC-based approach. WT or floxed Dlk mice were intravitreally injected with AAV2-expressing Cre and then subjected to ONC or sham surgery. Two days later, the number of double-positive TUBB3/phosphorylated-MEF2A cells was quantified by FC. Indeed, axon injury increased phosphorylation of MEF2A S408 in RGCs in vivo, in a manner that was highly dependent on the presence of DLK ( Figures 6E, S5A , and S5B). Collectively, these results highlight the ability of a wholegenome siRNA screen to be able to find novel and unexpected mediators of DLK-dependent cell death.
Sensitized, Whole-Genome siRNA Screen Identifies SOX11 as a Downstream Mediator of RGC Cell Death
The finding that LZK knockdown by itself did little to improve RGC survival, but greatly increased the effect of DLK knockdown, afforded an opportunity to perform a ''sensitized'' whole-genome siRNA screen for additional DLK pathway members. Each well was transfected with Lzk siPOOL (to sensitize the cells to DLK inhibition) and one of 16,698 siRNA minipools (comprised of four siRNAs each), in duplicate, challenged with colchicine 2 days later, and then assayed for viability after another 2 days. Using the common-seed method, we generated a list of the most survival-promoting siRNA minipools (Figure S6A) . Validating the approach, the top hit was the minipool targeting Dlk ( Figure 7A ). Moreover, other confirmed hits, including Atf2, Jun, Puma, Mkk4, Mkk7, , were all in the top 1% of genes ( Figure S6B ). Since none of the novel hits were confirmed when we tried to validate them with independent siRNAs (Figure S6C ), we turned to Haystack analysis to deconvolute the off-target effects. This analysis identified validated genes like Puma and Mkk4 ( Figure S6D ). Additionally, it identified Sox11, which was confirmed with independent siRNAs ( Figure S6E ). SOX11 is one of the most DLK-dependent, upregulated genes in the retina following ONC (Watkins et al., 2013) . However, along with SOX4, SOX11 is required for RGC differentiation and survival in development; thus, its role in RGC cell death was unexpected . In order to validate this finding, we first obtained an siPOOL targeting Sox11. After injury, consistent with the findings in vivo, primary RGCs upregulate Sox11 mRNA in a DLK/LZK-dependent and Sox11 siPOOL-sensitive manner ( Figure 7B ). Moreover, Sox11 siPOOLs had a mild survival-promoting effect that synergized with LZK knockdown ( Figure 7C ) and could be reversed with adenoviral expression of a mouse siPOOL-resistant, human SOX11 cDNA ( Figure 7D examined conditional Sox11 mice and found that RGCs isolated from floxed Sox11 mice had reduced cell death when transduced with Cre-, but not GFP-, expressing adenovirus ( Figure 7E ). Finally, using the mouse ONC model, we demonstrated that targeted deletion of Sox11 produced a statistically significant, albeit modest, increase in RGC survival in vivo ( Figure 7F ).
DLK/LZK-Dependent Cell Death Requires SOX11, MEF2A, JUN, and ATF2 Since targeted in vivo disruption of Sox11, Mef2a, Jun, and Atf2, one factor at a time, produced significant but modest improvements in RGC survival, we asked whether simultaneous inhibition of all four would lead to more robust neuroprotection. WT primary RGCs were transfected with siPOOLs against Atf2, Jun, Sox11, Mef2a, Dlk, or Lzk, alone or in various combinations, and assayed for survival ( Figure 8A ) and neurite outgrowth (Figure S7) . Consistent with the hypothesis, combined knockdown of all four transcription factors was highly survival-promoting and inhibitory to neurite outgrowth, rivaling the effect of combined DLZ/LZK knockdown. To test whether these factors were downstream of DLK/LZK, we turned to the LZK-reconstitution assay and found that combined knockdown of all four completely abrogated DLK/LZK-mediated cell death ( Figure 8B ). While highly suggestive, this result could have been confounded by siRNA off-target effects. Since breeding mice with conditional knockout alleles for all four transcription factors would be prohibitively time consuming, we developed a rapid CRISPR-based method to knockout genes, including in combination, in primary RGCs. RGCs were isolated from mice that express Streptococcus pyogenes Cas9 (SpCas9) from the Rosa26 locus (Platt et al., 2014) and transfected with T7-transcribed synthetic guide RNAs (sgRNAs). As a proof of principle, tracrRNA and six Dlk-targeting, chimeric sgRNAs were synthesized and cotransfected, along with Lzk siPOOL, into WT or SpCas9-expressing RGCs and assayed for their ability to inhibit cell death. Those sgRNAs that target Dlk, but not the control tracrRNA, were able to increase survival in the presence of SpCas9 ( Figure 8C ). Similar results were obtained in the reciprocal experiment with cotransfection of Lzk-targeting sgRNAs and Dlk siPOOL ( Figure 8D ) or with cotransfection of both Dlk-and Lzk-targeting sgRNAs (Figure 8E) . We then leveraged the fact that SpCas9-directed mutagenesis disrupts an endogenous BglII site in one of the Dlk targets and all of the most likely off-targets, to demonstrate that the system produces highly specific knockout ( Figure S8A ). Moreover, subcloning of the target site in the Dlk locus showed the typical spectrum of small indels ( Figure S8B ). Consistent with the siPOOL results, combined Dlk/Lzk targeting was far more robust than the addition of neurotrophins, although the combination led to a modest increase in survival ( Figure S8C ), a finding that may be relevant to future therapeutic strategies centered around DLK/LZK pathway inhibition. We then designed sgRNAs targeting Jun, Atf2, Mef2a, and Sox11 and showed that all four had modest survival-promoting activity when tested individually ( Figure 8F ). However, when combined, the four synergized to increase primary RGC survival to a level comparable to combined knockout of Dlk and Lzk. A similar degree of synergy was seen with an independent set of sgRNAs, arguing against an off-target-mediated phenotype ( Figure S8D ). Finally, CRISPR-based knockout of the four transcription factors rendered RGCs completely resistant to the effects of LZK pathway activation ( Figure 8G ). Taken together, these data reinforce the siRNA-based results and establish that SOX11, ATF2, JUN, and MEF2A cooperate to promote RGC cell death following DLK/LZK activation ( Figure 8H ). death. It is becoming increasingly appreciated that DLK plays a role as a key upstream trigger of this cascade (Shin et al., 2012; Watkins et al., 2013; Welsbie et al., 2013; Xiong et al., 2010) . In an effort to better define the DLK injury-signaling pathway, we have employed a variety of kinome-wide and whole-genome screens in conjunction with a disease-relevant primary neuron, the RGC. Using this unbiased and comprehensive functional genomic approach, we made the unexpected discoveries that cell death signaling can partially circumvent DLK and proceed through the related kinase, LZK, and that two transcription factors, SOX11 and MEF2A, previously only known to play a role in promoting neuronal survival, cooperate with ATF2 and JUN to execute the DLK/LZK-mediated cell death program. LZK was initially identified based on its homology to other MLKs (Sakuma et al., 1997) and, similar to the case with DLK, shown to have biochemical activity as an MKK7 kinase (Ikeda et al., 2001b) . Subsequently, it was found that developing motor neurons use MKK4, not MKK7, for DLK-dependent cell death (Itoh et al., 2014) . Using genetic deletion and rescue experiments, we have shown that LZK and DLK signaling in RGCs utilizes both MKK4 and MKK7, although further work will be required to dissect out the specific role for each. LZK can act as an intracellular mediator of PirB signaling, thought to be important in myelin's ability to retard axon growth (Dickson et al., 2010) . Interestingly, in primary RGCs, we have found that LZK has the opposite function, promoting neurite outgrowth after axotomy. Our finding is consistent with the recent report by Chen et al., who demonstrated that LZK can stimulate axon growth of cultured cerebellar granule neurons (CGNs) (Chen et al., 2016) . However, there also appear to be interesting differences between the activity of LZK in RGCs versus CGNs. As just noted above, LZK signaling in RGCs appears to go through both MKK4 and MKK7. This is distinct from CGNs, where LZK signaling seems to be mediated exclusively by MKK4, similar to that of DLK in motor neurons (Itoh et al., 2014) . That LZK inhibition alone decreases outgrowth, as well as our finding that the effect of DLK and LZK inhibition on neurite growth is additive, suggests that DLK and LZK have non-redundant roles in RGCs. Again, the mechanism may be different from the case in CGNs, as in that case the effect of DLK and LZK on axon growth is not additive (Chen et al., 2016) .
DISCUSSION
In contrast to the case with neurite outgrowth, in RGC cell death signaling DLK and LZK appear to be able to compensate for each other, at least partially, likely reflecting their participation in common biochemical complexes. The fact that LZK was not previously discovered to have a role in promoting neuronal cell death is perhaps surprising, given its structural and biochemical similarity to DLK, but it highlights the power and utility of unbiased phenotypic screens such as those that we employed here. From a therapeutic perspective, these results highlight the need to develop small-molecule inhibitors that target both DLK and LZK in order to treat neurodegenerative diseases related to axonopathy. However, as more is learned about the distinct functional roles of DLK and LZK, it may turn out to be desirable to develop drugs that can separately and independently modulate DLK and LZK activity. After axonal injury and/or cytoskeletal disruption activates DLK/LZK signaling, our data suggest that the four transcription factors SOX11, JUN, ATF2, and MEF2A are engaged and act as downstream mediators of cell death and, possibly, axon regeneration. Our SOX11 finding is consistent with the work of Norsworthy et al. (2017) , appearing in this issue, who using a totally independent approach identified SOX11 as playing a role in the death of RGCs following optic nerve crush. Highlighting the complexity of the response to axon injury, they found that SOX11 is preferentially involved in the death of a specific subclass of RGCs, alpha cells. Additionally, again consistent with our results, their data also implicates SOX11 in axon regeneration following crush. The finding of JUN and ATF2 involvement is not unexpected, as these factors are well known to be JNK regulated through phosphorylation following neuronal injury. More surprising are our findings related to MEF2A, since based on prior literature one would have expected the opposite result. MEF2A undergoes axon injury-triggered, DLK-dependent phosphorylation at S408, albeit not necessarily directly catalyzed by JNK. Typically, phosphorylation of MEF2A S408 leads to the sumoylation at K403 and the formation of a transcriptional repressor. This repressor has been shown to regulate synaptic differentiation (Shalizi et al., 2006) . Hitherto, MEF2A was known only to promote survival, with multiple groups showing MEF2A inactivation, either by phosphorylation or cleavage, triggering neuronal cell death (Gong et al., 2003; Okamoto et al., 2002) . We hypothesize that in RGCs, a transcriptional repressor form of MEF2A serves to downregulate the expression of pro-survival factors and tip the balance in favor of cell death. Importantly, when multiple MEF2 paralogs are disrupted, the survival increase is not attenuated, suggesting that the repressor must be doing more than simply interfering with the already-known, pro-survival effect of MEF2 signaling. Future profiling of the transcriptional changes mediated by MEF2A and, for that matter, JUN, ATF2, and SOX11, will help to clarify the relevant targets and understand how the cell death and regeneration signals bifurcate. We also recognize that our primary RGC assay is a mixture of RGC subtypes (Duan et al., 2015) and that some of the transcription factor synergy could reflect differing requirements in the different subtypes, as for example demonstrated in the results of Norsworthy et al. (2017) . Our evolving understanding of the role of DLK and LZK, and their downstream signaling and effector molecules, is providing new insights into the mechanisms by which axon injury is detected, how the injury signal is relayed to the cell body, and how this information is then interpreted so as to result in either cell death and/or a regenerative response. These new insights, in addition to increasing our understanding of basic neuronal processes, is opening possibilities for novel neuroprotective strategies for treatment of the optic neuropathies and other forms of neurodegenerative disease. Furthering this case for the potential clinical translatability of DLK/LZK inhibition, our data with human stem cell-derived RGCs shows that smallmolecule protein kinase inhibitors with activity against DLK and LZK, including an already FDA approved drug, sunitinib, are also active in promoting the survival of human neurons.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
